MDimune announces a collaboration with Hanyang University on the projects selected through the 3rd BioDrone Award

Logo EIN Presswire
EIN Presswire
SEONGDONG-GU, SEOUL, SOUTH KOREA, January 26, 2023 /EINPresswire.com/ -- MDimune Inc., a Korean biotech company developing BioDrone platform technology based on cell-derived vesicles (CDVs), announces funding of two research projects focusing on next-generation drug delivery and novel therapeutics. The projects were selected through the 3rd BioDrone Award held in October 2022. For these projects, MDimune signed an MOU with Hanyang University to collaborate with the research teams of Doory Kim, Ph.D. (Super-resolution Spectroscopic Microscopy Lab) and Hee Ho Park, Ph.D. (Cell and Nanotherapy Engineering lab).

In 2020, MDimune launched a call for research proposals, BioDrone Award, to stimulate innovative research to develop and advance next-generation drug delivery platform technology. This yearly award is open to scientists in all career stages who are affiliated with a research-based institution, not limited to researchers in Korea. In 2021, Giorgia Pastorin, Ph.D. (National University of Singapore) was awarded via Global BioDrone Award and collaborated with the company.

We are very excited to announce the 3rd BioDrone Award recipients. This year again, we received numerous proposals with innovative technologies and excellent ideas, and we truly appreciate all the participants. For selection, we focused on the capacity of the projects which can improve the application of cargo-loading, targeting, and extrusion-based novel technology. In the past, we have successfully collaborated with talented researchers identified through the Award and we expect that our new research collaboration with Hanyang University research teams will be also productive and fruitful to advance our BioDrone Platform technology, said Shin-Gyu Bae, the Chief Executive Officer of MDimune.

With the expertise of Dr. Kim, we expect to have a better understanding of the intracellular mechanism of CDV as a drug delivery platform, and it will help us to engineer CDV to improve or modulate its capacity. Dr. Parks project will strengthen our cancer therapeutics program, added Seung-Wook Oh, the Chief Scientific Officer of MDimune.

The company has been dedicated to developing a novel drug delivery platform using CDV, a type of extracellular vesicle (EV) generated by a proprietary extrusion method. Due to its molecular characteristics and potency with higher production yield compared to native exosomes, the CDV has promising potential as a drug delivery platform with minimized adverse effects and maximized efficacy. The company is expecting to enter the clinical stage during the last quarter of 2023.


The 3rd BioDrone Award recipients:
Doory Kim, Ph.D., Assistant Professor, Department of Chemistry, Hanyang University
Project: Investigation of intracellular drug delivery mechanism using super-resolution nanoimaging technology
Hee Ho Park, Ph.D. Assistant Professor, Department of Bioengineering, Hanyang University
Project: Development of cancer therapeutics by engineering CAR-T cell-derived nanovesicle

About MDimune
MDimune Inc., founded in 2015, is a biotech company headquartered in Seoul, Korea, and has been dedicated to the development of the innovative therapeutic platform BioDrone. The novel BioDrone platform technology uses cell-derived vesicles to overcome the limitations of existing cell therapies or achieve target-specific drug delivery. BioDrone platform technology is patented in the US, Europe, China, Japan, and Korea. MDimune is actively pursuing business partnerships with biotech and pharmaceutical companies for the potential application of the BioDrone technology for various unmet medical needs. For more information, please visit the company's websites, http://www.mdimune.com/, https://biodroneus.com/

Jisun Lee
MDimune Inc.
bd@mdimune.com

Continue read on einpresswire.com

Logo PR Newswire
HealthPress Release2023-01-26 01:00:00
SEOUL, South Korea, Jan. 25, 2023 /CNW/ -- GenKOre, Inc., a Korea-based biotech company with hypercompact CRISPR-Cas tools, announced that it has entered...

Logo PR Newswire
TechnologyPress Release2023-01-25 13:00:00
PALO ALTO, Calif., Jan. 25, 2023 /PRNewswire/ -- Deep Forest Sciences, Inc., a startup that accelerates chemical matter discovery and optimization is...

Logo PR Newswire
NANJING, China, Jan. 25, 2023 /PRNewswire/ -- As the tissue engineering and regenerative treatment industry has shown tremendous potential in clinical...

Logo PR Newswire
HealthPress Release2023-01-25 23:00:00
DUBLIN, Jan. 25, 2023 /PRNewswire/ -- The "Global Gene Therapy Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-25 15:31:00
Investment from Leading Duchenne Organization Contributes To Seed Funding Round Totaling Over $5 Million, Builds on Earlier PPMD Investment Which Facilitated...

Logo GlobeNewswire
SciencePress Release2023-01-25 13:00:00
First Immunosynthen ADC product candidate enters the clinic CAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a...

Logo EIN Presswire
New appointments and partnerships will focus on supporting industry, science and policy collaboration in tech-focused sectors

Logo GlobeNewswire
SciencePress Release2023-01-25 12:00:00
BOCA RATON, Fla., Jan. 25, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (First Wave BioPharma or the Company), a clinical-stage...

Logo PR Newswire
HealthPress Release2023-01-25 15:53:00
Caron continues to serve the greater humanity in positive ways achieving their seventh patent MARIETTA, Ohio, Jan. 25, 2023 /PRNewswire/ -- Caron Products...

Logo Benzinga
Business / FinanceBy Globe Newswire2023-01-25 09:00:00
- Claus Andersson, PhD, joins Rewinds Board of Directors Leuven, Belgium, January 25, 2023 --- Rewind Therapeutics, a company developing first-in-class...

Logo PR Newswire
HealthPress Release2023-01-25 18:50:00
DUBLIN, Jan. 25, 2023 /PRNewswire/ -- The "CRISPR Technology: Global Markets" report has been added to ResearchAndMarkets.com's offering. A $9.2 Billion...

Logo PR Newswire
HealthPress Release2023-01-24 11:30:00
BOSTON, Jan. 24, 2023 /PRNewswire/ -- NanoMosaic, the pioneer and leader of nanoneedle technology (MosaicNeedle™) for proteomics and multiomics, announced...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 07:00:00
Axion BioSystems, a leader in live-cell analysis tools, today announced the full integration of imaging innovator CytoSMART Technologies into the Axion...

Logo PR Newswire
DUBLIN, Jan. 25, 2023 /PRNewswire/ -- The "Automated and Closed Cell Therapy Processing Systems Market by Workflow, Type, Scale, and by Region - Global...

Logo PR Newswire
HealthPress Release2023-01-25 15:13:00
MILWAUKEE, Jan. 25, 2023 /PRNewswire/ -- GenoPalate, Inc., a Milwaukee -based nutritional genomics company, is launching GenoVit, a new line of personalized...

Logo PR Newswire
TechnologyPress Release2023-01-25 13:30:00
MOUNTAIN VIEW, Calif., Jan. 25, 2023 /PRNewswire/ -- Health Gorilla, a Health Information Network (HIN) and leading interoperability platform, has launched...

Logo GlobeNewswire
SciencePress Release2023-01-25 13:30:00
Isranalytica 2023, the A nnual meeting of the Israel Analytical Chemical Society, provided Clearmind with the opportunity to garner visibility for its drug...

Logo Benzinga
Business / FinanceBy Globe Newswire2023-01-24 19:10:00
- Wednesday, January 25, 202 3 1 0 : 50 am 11:20am EST - Discussion of the Biotech Showcase Conference BOSTON, MASSACHUSETTS, Jan. 24, 2023 (GLOBE NEWSWIRE)...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-25 13:02:00
Capital investment led by John Ballantyne will support optimization of the company's muscle-specific non-viral gene therapy platform, moving closer to...

Logo GlobeNewswire
SciencePress Release2023-01-25 09:00:00
HANNOVER, Germany, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vakzine Projekt Management GmbH (VPM), a German drug development consultancy and service provider...